Enlivex Therapeutics (NASDAQ:ENLV) Rating Lowered to “Hold” at D Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by investment analysts at D Boral Capital from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages have also issued reports on ENLV. D. Boral Capital restated a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Enlivex Therapeutics in a report on Tuesday, September 2nd. Wall Street Zen raised Enlivex Therapeutics to a “sell” rating in a research report on Saturday, August 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Enlivex Therapeutics in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

Enlivex Therapeutics Price Performance

Enlivex Therapeutics stock opened at $0.98 on Monday. The stock has a market capitalization of $23.81 million, a P/E ratio of -1.69 and a beta of 1.20. Enlivex Therapeutics has a 12-month low of $0.83 and a 12-month high of $2.10. The firm’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.11.

Institutional Investors Weigh In On Enlivex Therapeutics

Several large investors have recently made changes to their positions in the business. Citizens Financial Group Inc. RI purchased a new position in shares of Enlivex Therapeutics in the 3rd quarter valued at $241,000. Jane Street Group LLC raised its position in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after purchasing an additional 67,886 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in Enlivex Therapeutics in the third quarter valued at about $57,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.